Lilly’s Pegilodecakin Fails Pancreatic Cancer Test
Asset came from $1.6bn Armo buy
Executive Summary
The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.